Joel M. Reid

TL;DR: The vitreous half-life of 1.25 mg intravitreal bevacizumab (Avastin) is 4.32 days in a rabbit eye, compared with 4.88 days and 6.86 days for the aqueous and serum values, respectively.

TL;DR: It is demonstrated that expression and activity of the NADase CD38 increase with aging and that CD38 is required for the age-related NAD decline and mitochondrial dysfunction via a pathway mediated at least in part by regulation of SIRT3 activity.

TL;DR: Although vitreous concentrations of ranibizumab declined in a monoexponential fashion with a half-life of 2.88 days, concentrations of >0.1 microg/ml ranibzumab were maintained in the Vitreous humor for 29 days, whereas small amounts of intravitreal bevacizumAB have been detected in the serum and fellow uninjected eye.

TL;DR: Both target suppression and antitumor activity were demonstrated in this phase I study of CI-1040, a small-molecule inhibitor of the dual-specificity kinases MEK -1 and MEK2 in patients with advanced malignancy.

TL;DR: In this article, a family of structurally homologous nanoparticles, including neutral (TEGOH), zwitterionic (Tzwit), negative (TCOOH), and positive (TTMA), were injected into mice to investigate how surface properties such as charge played an important role in their in vivo behavior.